Publication
International Restructuring Newswire
Welcome to the Q2 2024 edition of the Norton Rose Fulbright International Restructuring Newswire.
Author:
Publication | March 2017
Treaty/Act: CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures)
Date: March 7, 2017 – Bill C-30 passes second reading in Senate and is referred to Senate’s Standing Committee on Foreign Affairs and International Trade
Major reforms to Canada’s Patent Act are coming as the Canadian Parliament moves one step closer to ratifying the Comprehensive Economic and Trade Agreement (CETA). On March 7, 2017, Bill C-30 (the Act intended to implement CETA into Canadian law) passed its second reading in the Senate, placing it in the final stages of the legislative process. Recent media reports indicate the European Union’s trade chief expects that Canada will ratify CETA within weeks.1
As we reported, CETA and Bill C-30 provide key reforms to the Patent Act affecting the pharmaceutical industry, including:
Are you CETA ready? Contact Norton Rose Fulbright with all your CETA questions.
Bill C-30, Third Reading (House of Commons)
Text of the final Comprehensive Economic and Trade Agreement
1. http://globalnews.ca/news/3324454/canada-eu-to-ratify-free-trade-pact/
Publication
Welcome to the Q2 2024 edition of the Norton Rose Fulbright International Restructuring Newswire.
Publication
The Canadian Federal Budget 2024 proposes to broaden the scope of certain powers allowing CRA to request information from taxpayers, and sets out new consequences for non-compliant taxpayers.
Publication
The alternative minimum tax is an additional income tax imposed under the Income Tax Act on individuals and certain trusts who would otherwise be able to reduce their ordinary Canadian federal income tax through the use of certain deductions, exemptions or credits.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023